Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,541,963
-
Share change
-
+885,257
-
Total reported value
-
$6,489,816
-
Put/Call ratio
-
0%
-
Price per share
-
$1.80
-
Number of holders
-
34
-
Value change
-
+$1,630,740
-
Number of buys
-
16
-
Number of sells
-
9
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q2 2025
As of 30 Jun 2025,
Gain Therapeutics, Inc. - COM (GANX) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,541,963 shares.
The largest 10 holders included
JONES FINANCIAL COMPANIES LLLP, DME Capital Management, LP, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, MARSHALL WACE, LLP, Cambridge Investment Research Advisors, Inc., CITADEL ADVISORS LLC, BlackRock, Inc., NORTHERN TRUST CORP, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.